Biotech News

Liquidia Provides Update on Hatch-Waxman Litigation Tied to ‘327 Patent

Liquidia Corporation (LQDA)Liquidia CorporationCompany update

District Court ruled that two of the six claims asserted against Liquidia are valid and infringed Parties directed to submit form of judgment, specifying the proposed remedy, for the District Court’s consideration within one week MORRISVILLE, N.C., Sept.

Related news

Liquidia Corporation

Pulmonary Hypertension Company Liquidia develops and commercializes therapies for pulmonary hypertension. Its product strategy applies particle-engineering technology to improve delivery of established medicines. YUTREPIA YUTREPIA is a dry-powder formulation of treprostinil delivered through a compact, low-effort inhaler. It is approved...

Recent company news

Stock data

Close
27.99 USD
Market cap
4.9B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States